
-
Denali Therapeutics NasdaqGS:DNLI Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Location: 161 Oyster Point Boulevard, South San Francisco, CA, 94080, United States | Website: https://www.denalitherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.201B
Cash
817.9M
Avg Qtr Burn
-91.39M
Short % of Float
9.27%
Insider Ownership
9.94%
Institutional Own.
94.26%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
DNL310 (tividenofusp alfa) Details Hunter syndrome MPS II | BLA Submission | |
DNL343 (eIF2B Activator) Details Amyotrophic lateral sclerosis | Phase 2/3 Data readout | |
BIIB122/DNL151 (LRRK2 Inhibitor) Details Parkinson's disease | Phase 2b Data readout | |
SAR443820/DNL788 (CNS-Penetrant RIPK1 Inhibitor) Details Multiple sclerosis | Phase 2 Data readout | |
DNL758 (CNS-penetrant RIPK1 inhibitor) Details Lupus nephritis, Cutaneous lupus erythematosus, Ulcerative colitis | Phase 2 Data readout | |
BIIB122 (DNL151) Details Parkinson's disease | Phase 2a Data readout | |
TAK-594/DNL593 (PTV:PGRN) Details Frontotemporal dementia with GRN mutations | Phase 1/2 Data readout | |
DNL126 (ETV:SGSH) Details Sanfilippo Syndrome | Phase 1/2 Update | |
SAR443820/DNL788 (CNS-Penetrant RIPK1 Inhibitor) Details Amyotrophic lateral sclerosis | Failed Discontinued |